Lefebvre Véronique, Dvir-Ginzberg Mona
a Department of Cellular and Molecular Medicine , Cleveland Clinic Lerner Research Institute , Cleveland , OH , USA.
b Faculty of Dental Medicine , Institute of Dental Sciences, Hebrew University of Jerusalem , Jerusalem , Israel.
Connect Tissue Res. 2017 Jan;58(1):2-14. doi: 10.1080/03008207.2016.1183667. Epub 2016 Apr 29.
SOX9 is a pivotal transcription factor in developing and adult cartilage. Its gene is expressed from the multipotent skeletal progenitor stage and is active throughout chondrocyte differentiation. While it is repressed in hypertrophic chondrocytes in cartilage growth plates, it remains expressed throughout life in permanent chondrocytes of healthy articular cartilage. SOX9 is required for chondrogenesis: it secures chondrocyte lineage commitment, promotes cell survival, and transcriptionally activates the genes for many cartilage-specific structural components and regulatory factors. Since heterozygous mutations within and around SOX9 were shown to cause the severe skeletal malformation syndrome called campomelic dysplasia, researchers around the world have worked assiduously to decipher the many facets of SOX9 actions and regulation in chondrogenesis. The more we learn, the more we realize the complexity of the molecular networks in which SOX9 fulfills its functions and is regulated at the levels of its gene, RNA, and protein, and the more we measure the many gaps remaining in knowledge. At the same time, new technologies keep giving us more means to push further the frontiers of knowledge. Research efforts must be pursued to fill these gaps and to better understand and treat many types of cartilage diseases in which SOX9 has or could have a critical role. These diseases include chondrodysplasias and cartilage degeneration diseases, namely osteoarthritis, a prevalent and still incurable joint disease. We here review the current state of knowledge of SOX9 actions and regulation in the chondrocyte lineage, and propose new directions for future fundamental and translational research projects.
SOX9是发育中和成年软骨中的关键转录因子。其基因从多能骨骼祖细胞阶段开始表达,并在软骨细胞分化过程中一直保持活跃。虽然它在软骨生长板的肥大软骨细胞中受到抑制,但在健康关节软骨的永久性软骨细胞中终生表达。软骨形成需要SOX9:它确保软骨细胞谱系的定向分化,促进细胞存活,并转录激活许多软骨特异性结构成分和调节因子的基因。由于SOX9内部及其周围的杂合突变被证明会导致严重的骨骼畸形综合征——弯肢侏儒症,世界各地的研究人员一直在努力解读SOX9在软骨形成中的作用和调控的多个方面。我们了解得越多,就越意识到SOX9在其中发挥功能并在其基因、RNA和蛋白质水平受到调控的分子网络的复杂性,也越能衡量出知识中仍存在的许多空白。与此同时,新技术不断为我们提供更多手段来进一步拓展知识前沿。必须开展研究工作来填补这些空白,以便更好地理解和治疗多种类型的软骨疾病,其中SOX9已经或可能发挥关键作用。这些疾病包括软骨发育异常和软骨退行性疾病,即骨关节炎,一种普遍且仍无法治愈的关节疾病。我们在此回顾了关于SOX9在软骨细胞谱系中的作用和调控的当前知识状态,并为未来的基础研究和转化研究项目提出了新的方向。